• Most Popular
  • Most Shared

Hana says anti-cancer drug gets fast-track designation

Wed Aug 22, 2007 7:24am EDT

Aug 22 (Reuters) - Biopharmaceutical company Hana Biosciences HNAB.O said U.S. health regulators granted fast-track designation to its anti-cancer drug, Marqibo.

The company said Marqibo received the status for the treatment of adults with Philadelphia chromosome negative acute lymphoblastic leukemia in second relapse, or for those who have failed two lines of prior therapy. Marqibo was also granted orphan drug designation by the Food and Drug Administration for the treatment of adult acute lymphoblastic leukemia earlier this year, Hana added. (Reporting by Esha Dey in Bangalore)



More from Reuters

Photo

U.S. pay czar Feinberg OKs compensation at some bailout firms

WASHINGTON (Reuters) - U.S. pay czar Kenneth Feinberg on Wednesday approved compensation plans for several executives and top-paid employees at three firms that have received taxpayer aid.

» More Top News
A man dressed as talks on a telephone during his visit at the Benjamin Bloom National Children Hospital in San Salvador December 17, 2009.

Making the call on stocks

Looking for something special to put under your favorite investor's tree? These shares may provide the best upside surprise.  Full Article 

Healthcare reform
A customer orders food at the newly opened Island Salad restaurant in Harlem in New York December 16, 2009. REUTERS/Finbarr O'Reilly

Food fight in Harlem

In a neighborhood where hamburgers and tacos reign supreme, one entrepreneur is waging war on obesity -- one salad at a time.  Full Article 

Lifestyle